HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells

Leukemia Research

Volumn 32, Issue 6, 2008, Pages 962-971

  Sugimoto, Yuya ^a   Nakamura, Satoki ^a   Okinaka, Keiji ^a   Hirano, Isao ^a   Ono, Takaaki ^a   Shigeno, Kazuyuki ^a   Shinjo, Kaori ^a   Ohnishi, Kazunori ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bcr Abl; CML; HOXA10; Stem cells

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ABELSON KINASE; DASATINIB; IMATINIB; NILOTINIB; TRANSCRIPTION FACTOR HOXA10;

ADULT; APOPTOSIS; ARTICLE; CASE REPORT; CELL POPULATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW; CASE-CONTROL STUDIES; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; COLONY-FORMING UNITS ASSAY; DNA PRIMERS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELLS; HOMEODOMAIN PROTEINS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MORPHOLINES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; THIAZOLES; TRANSFECTION;

EID: 40849126769     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.034     Document Type: Article

References (34)

1. Kurzrock R., Gutterman J.U., and Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319 (1988) 990-998
2. Rudkin C.T., Nowell P.C., and Hungerford D.A. DNA contents of chromosome Ph1 and chromosome 21 in human chronic granulocytic leukemia. Science 144 (1964) 1229-1231
3. Shtivelman E., Lifshitz B., Gale R.P., and Ganaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315 (1985) 550-554
4. Lugo T.G., Pendergast A.M., Muller A.J., and Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 (1990) 1079-1082
5. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
6. Peggs K., and Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348 (2003) 1048-1050
7. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
8. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (2001) 1038-1042
9. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 (2002) 1928-1937
10. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of wild-type and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
11. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
12. O'hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
13. Giles F., Kantarjian H., Wassmann B., et al. A phase I/II study of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, on a continuous daily dosing schedule in adult patients with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL). Blood 104 (2004) 10a
14. Michor F., Hughes T.P., Iwase Y., et al. Dynamics of chronic myeloid leukemia. Nature 435 (2005) 1267-1270
15. Lawrence H.J., Sauvageau G., Humphries R.K., and Largman C. The role of HOX homeobox genes in normal and leukemic hematopoiesis. Stem Cells 14 (1996) 273-291
16. Magli M.C., Largman C., and Lawrence H.J. Effects of HOX homeobox genes in blood cell differentiation. J Cell Physiol 173 (1996) 168-177
17. Boncinelli E., Acampora D., Pannese M., et al. Organization of human class I homeobox genes. Genome 31 (1989) 745-756
18. Zeltser L., Desplan C., and Heintz N. Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains colinearity. Development 122 (1996) 2475-2484
19. + subpopulations of human bone marrow cells. Proc Natl Acad Sci USA 91 (1994) 12223-12227
20. Lawrence H.J., Sauvageau G., Ahmadi N., et al. Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells. Exp Hematol 23 (1995) 1160-1166
21. Buske C., Feuring-Buske M., Antonchuk J., et al. Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood 97 (2001) 2286-2292
22. Thorsteinsdorttir U., Sauvageau G., Hough M.R., et al. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol 17 (1997) 495-505
23. Taghon T., Stolz F., De Smedt M., et al. HOX-A10 regulates hematopoietic lineage commitment: evidence for a monocyte-specific transcription factor. Blood 99 (2002) 1197-1204
24. Bjomsson J.M., Andersson E., Lundstrom P., et al. Proliferation of primitive myeloid progenitors can reversibly induced by HOXA10. Blood 98 (2001) 3301-3308
25. Bromleigh V.C., and Freedman L.P. P21 is a transcriptional target of HOXA10 in differentiating myelomonocytic cells. Genes Dev 14 (2000) 2581-2586
26. Eklind E.A., Kakar R., and Jalava A. HoxA10 recruits transcriptional co-repressors to the CYBB and NCF2 genes. Blood 96 (2000) 286a
27. Saleh M., Rambaldi I., Yang X.J., and Featherstone M.S. Cell signaling switches HOX-PBX complexes from repressors to activators of transcription mediated by histone deacetylases and histone acetyltransferases. Mol Cell Biol 20 (2000) 8623-8633
28. Manley P.W., Cowan-Jacob S.W., and Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukemia. Biochem Biophys Acta 1754 (2005) 3-13
29. Andreu E.J., Lledo E., Poch E., et al. Bcr-Abl induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 65 (2005) 3264-3272
30. Klejman A., Rushen L., Morrione A., et al. Posphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21 (2002) 5868-5876
31. Sattler M., Mohi M.G., Pride Y.B., et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2001) 479-492
32. Stanglmaier M., Warmuth M., Kleinein I., et al. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 17 (2003) 283-289
33. Sattler M., Salgia R., Okuda K., et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to phosphatidylinositol-3′ kinase pathway. Oncogene 12 (1996) 839-846
34. Bartolovic K., Balabanov S., Hartmann U., et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103 (2004) 523-529